GlassScriptPhysician profile
Jonathon A Bannwarth
NPI 1184044273
$1,100.14
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $985 · 2020: $101 · 2023: $13.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $159.64 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.58 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $133.97 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $121.53 | 2019 | |
| Glaxosmithkline, LLC. | $109.16 | 2019 | |
| Dexcom, INC. | $91.47 | 2019-2020 | |
| Amgen INC. | $85.86 | 2019-2023 | |
| Pfizer INC. | $83.37 | 2019-2020 | |
| Novo Nordisk INC | $66.18 | 2019-2020 | |
| Grifols USA, LLC | $26.94 | 2019 | |
| Gilead Sciences, INC. | $14.49 | 2019 | |
| Genentech USA, INC. | $13.30 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.84 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.84 | 2019 | |
| Sanofi-Aventis U.S. LLC | $10.97 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathon Bannwarth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.